Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PHILLIP KUNISADA KIYASU

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1124010673
CMS profile
322489
Location
PORTLAND, OR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$181.29

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $155.59 2
Education $25.70 1

By paying entity

PY2025 · entire year · sorted by reported total

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PHILLIP KUNISADA KIYASU

NPI 1124010673 · CMS profile ID 322489

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

PORTLAND, OR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1124010673?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PHILLIP KUNISADA KIYASU, NPI 1124010673, CMS profile ID 322489. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1124010673?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). PHILLIP KUNISADA KIYASU, NPI 1124010673, CMS profile ID 322489. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1124010673?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
PHILLIP KUNISADA KIYASU, NPI 1124010673, CMS profile ID 322489, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1124010673?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $181.29 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Takeda Pharmaceuticals U.S.A., Inc. $30.5910/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223923591 CMS
Janssen Scientific Affairs, LLC $125.0009/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174188756 CMS
Merck Sharp & Dohme LLC $25.7005/02/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1237995098 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2023 $19.25 1
PY2024 $35.32 1
PY2025 $181.29 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $176,619.14 77
PY2024 Principal investigator $162,757.47 113
PY2023 Principal investigator $137,395.30 56
PY2022 Principal investigator $8,085.15 7
PY2021 Principal investigator $5,000.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

77 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $157.00 12/17/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175263295
Principal investigator 1 Janssen Research & Development, LLC $157.00 12/17/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175263903
Principal investigator 1 Janssen Research & Development, LLC $33,602.00 12/15/2025 Non-covered Recipient Entity
THE OREGON CLINIC PC
A Phase 3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol in Adults with an Open Label Study in Adolescents to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy with Icotrokinra in Participants With Moderately to Severely Active Ulcerative Colitis ICONIC-UC No dispute reported 06/30/2026 1175434628
Principal investigator 1 Janssen Research & Development, LLC $34,331.00 12/12/2025 Non-covered Recipient Entity
THE OREGON CLINIC PC
A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol to Evaluate the Efficacy and Safety of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175434547
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $444.00 12/10/2025 Non-covered Recipient Entity
THE OREGON CLINIC PC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223289466
Principal investigator 1 Janssen Research & Development, LLC $2,247.00 10/27/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175263428
Principal investigator 1 Janssen Research & Development, LLC $3,370.00 10/27/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175263980
Principal investigator 1 Janssen Research & Development, LLC $2,247.00 10/27/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175264059
Principal investigator 1 Janssen Research & Development, LLC $157.00 09/29/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175263834
Principal investigator 1 Genentech, Inc. $1,000.00 09/24/2025 Non-covered Recipient Entity
THE OREGON CLINIC PC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211667596
Principal investigator 1 Genentech, Inc. $375.00 09/19/2025 Non-covered Recipient Entity
THE OREGON CLINIC PC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211667600
Principal investigator 1 Janssen Research & Development, LLC $25.00 09/10/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175263656
Principal investigator 1 Janssen Research & Development, LLC $157.00 08/21/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175263193
Principal investigator 1 Janssen Research & Development, LLC $157.00 08/21/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175263579
Principal investigator 1 Janssen Research & Development, LLC $157.00 08/21/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175263729
Principal investigator 1 Genentech, Inc. $177.61 08/20/2025 Non-covered Recipient Entity
THE OREGON CLINIC PC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211667590
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $444.00 08/06/2025 Non-covered Recipient Entity
THE OREGON CLINIC PC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223283831
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $444.00 08/06/2025 Non-covered Recipient Entity
THE OREGON CLINIC PC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223283833
Principal investigator 1 Janssen Research & Development, LLC $2,247.00 07/28/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175263595
Principal investigator 1 Janssen Research & Development, LLC $2,247.00 07/28/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175263604
Principal investigator 1 Janssen Research & Development, LLC $3,370.00 07/28/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175264139
Principal investigator 1 Janssen Research & Development, LLC $800.00 07/21/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175263708
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $444.00 07/07/2025 Non-covered Recipient Entity
THE OREGON CLINIC PC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223282362
Principal investigator 1 Genentech, Inc. $344.00 07/04/2025 Non-covered Recipient Entity
THE OREGON CLINIC PC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211667592
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $875.00 06/16/2025 Non-covered Recipient Entity
THE OREGON CLINIC PC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223281280
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $40.00 06/16/2025 Non-covered Recipient Entity
THE OREGON CLINIC PC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223281282
Principal investigator 1 Genentech, Inc. $131.65 06/13/2025 Non-covered Recipient Entity
THE OREGON CLINIC PC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211667587
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 06/12/2025 Non-covered Recipient Entity
THE OREGON CLINIC PC
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184206685
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,625.00 06/12/2025 Non-covered Recipient Entity
THE OREGON CLINIC PC
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184206687
Principal investigator 1 Janssen Research & Development, LLC $25.00 06/02/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175263336
Principal investigator 1 Genentech, Inc. $1,251.00 05/23/2025 Non-covered Recipient Entity
THE OREGON CLINIC PC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211667584
Principal investigator 1 Janssen Research & Development, LLC $157.00 05/12/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175263486
Principal investigator 1 Janssen Research & Development, LLC $130.00 05/12/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175263538
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $444.00 05/07/2025 Non-covered Recipient Entity
THE OREGON CLINIC PC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223278984
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $444.00 05/07/2025 Non-covered Recipient Entity
THE OREGON CLINIC PC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223278986
Principal investigator 1 Janssen Research & Development, LLC $220.00 04/30/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175264126
Principal investigator 1 Janssen Research & Development, LLC $3,250.00 04/28/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175263223
Principal investigator 1 Janssen Research & Development, LLC $343.00 04/28/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175263276
Principal investigator 1 Janssen Research & Development, LLC $2,247.00 04/28/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175263319
Principal investigator 1 Janssen Research & Development, LLC $3,250.00 04/28/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175263436
Principal investigator 1 Janssen Research & Development, LLC $2,247.00 04/28/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175263503
Principal investigator 1 Janssen Research & Development, LLC $3,237.00 04/28/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175263511
Principal investigator 1 Janssen Research & Development, LLC $6,009.00 04/28/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175263722
Principal investigator 1 Janssen Research & Development, LLC $25.00 04/09/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175263913
Principal investigator 1 Janssen Research & Development, LLC $5,871.00 04/03/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175263240
Principal investigator 1 Janssen Research & Development, LLC $500.00 04/03/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175263396
Principal investigator 1 Janssen Research & Development, LLC $800.00 04/03/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175263811
Principal investigator 1 Janssen Research & Development, LLC $250.00 04/03/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175264066
Principal investigator 1 Genentech, Inc. $42,534.00 04/02/2025 Non-covered Recipient Entity
THE OREGON CLINIC PC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211667580
Principal investigator 1 Janssen Research & Development, LLC $500.00 03/27/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175263250
Principal investigator 1 Janssen Research & Development, LLC $250.00 03/27/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175263357
Principal investigator 1 Janssen Research & Development, LLC $25.00 03/27/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175263804
Principal investigator 1 Janssen Research & Development, LLC $440.00 03/27/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175263893
Principal investigator 1 Janssen Research & Development, LLC $239.00 03/25/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175263564
Principal investigator 1 Janssen Research & Development, LLC $50.00 03/25/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175263624
Principal investigator 1 Janssen Research & Development, LLC $200.00 03/25/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175263824
Principal investigator 1 Janssen Research & Development, LLC $217.00 03/25/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175263857
Principal investigator 1 Janssen Research & Development, LLC $157.00 03/25/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175263986
Principal investigator 1 Janssen Research & Development, LLC $492.00 03/25/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175264023
Principal investigator 1 Janssen Research & Development, LLC $152.00 03/25/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175264109
Principal investigator 1 Janssen Research & Development, LLC $157.00 03/20/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175264152
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $444.00 03/12/2025 Non-covered Recipient Entity
THE OREGON CLINIC PC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223276303
Principal investigator 1 Genentech, Inc. $121.88 03/05/2025 Non-covered Recipient Entity
THE OREGON CLINIC PC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211667576
Principal investigator 1 Janssen Research & Development, LLC $190.00 03/03/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175263188
Principal investigator 1 Janssen Research & Development, LLC $141.00 03/03/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175263665
Principal investigator 1 Janssen Research & Development, LLC $126.00 03/03/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175263676
Principal investigator 1 Janssen Research & Development, LLC $150.00 03/03/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175263736
Principal investigator 1 Janssen Research & Development, LLC $51.00 03/03/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175263946
Principal investigator 1 Janssen Research & Development, LLC $274.00 03/03/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175264044
Principal investigator 1 Janssen Research & Development, LLC $25.00 01/29/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175263703
Principal investigator 1 Janssen Research & Development, LLC $500.00 01/27/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175263214
Principal investigator 1 Janssen Research & Development, LLC $2,517.00 01/27/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175263715
Principal investigator 1 Janssen Research & Development, LLC $520.00 01/27/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175263786
Principal investigator 1 Janssen Research & Development, LLC $800.00 01/27/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175263923
Principal investigator 1 Janssen Research & Development, LLC $130.00 01/27/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175264052
Principal investigator 1 Janssen Research & Development, LLC $800.00 01/08/2025 Non-covered Recipient Entity
The Oregon Clnc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175264008
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $444.00 01/08/2025 Non-covered Recipient Entity
THE OREGON CLINIC PC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223273695